Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Eur J Heart Fail. 2015 Aug 6;17(9):925–935. doi: 10.1002/ejhf.327

Table 2b.

Probability of primary outcome and secondary outcomes at 3 years according to subgroup in CHARM-Preserved, candesartan vs. placebo, % (95% CI)

Subgroup Placebo
Candesartan
Total Primary, % Secondary, % Total Primary, % Secondary, %
A 329 32 (27–37) 12 (9–16) 348 31 (26–36) 11 (8–14)
B 125 33 (26–42) 10 (6–17) 134 28 (21–36) 10 (6–16)
C 144 56 (48–64) 36 (28–44) 144 55 (47–64) 29 (22–38)
D 317 39 (34–45) 19 (15–24) 287 33 (28–39) 13 (10–18)
E 415 41 (36–46) 17 (14–21) 444 38 (34–43) 15 (12–19)
F 175 54 (47–62) 35 (28–43) 157 53 (46–62) 28 (22–37)